ALPMF News and Press, Astellas Pharma Inc From 01/06/21

Astellas Pharma (ALPMF) announces that the FDA has granted priority reviews for marketing application seeking approval for mirabegron for oral suspension and supplemental application for Myrbetriq (mirabegron) tablets for neurogenic detrusor overactivity ((NDO)) in pediatric patient...

FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline consists of two late-stage/commercialized therapeutics and one medical product all with seve...

Astellas' (ALPMF) Xospata (gilteritinib) in combination with azacitidine did not meet the primary endpoint of overall survival at an interim analysis of Phase 3 trial, LACEWING in acute myeloid leukemia ((AML)) patients.Independent data monitoring committee recommended terminating the study f...

FibroGen (FGEN) announced that the FDA has extended the review period of its NDA for Roxadustat by three months, with an updated action date set for March 20.In February, the company announced that the FDA accepted the NDA for Roxadustat in the treatment for anemia of chronic kidney disease. ...

Year to date, WTGDXG has outperformed its benchmark-the MSCI ACWI ex-US Index - by more than 800 basis points (bps), thanks to its quality dividend growth tilt. Fundamentals after our rebalance show a significant increase in quality metrics. ROA improves from 8.77% to 10.31%, and ROE ...

Japan's Ministry of Health, Labor and Welfare has approved Astellas Pharma (ALPMF) and FibroGen's (FGEN) EVRENZO (roxadustat) for the treatment of anemia in non-dialysis-dependent adults with stage 3-5 chronic kidney disease.The approval is based on results obtained from three ...

The China National Medical Products Administration has approved Astellas Pharma's (ALPMF) XTANDI (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.This is the second approved indicati...

Astellas Pharma Inc. (ALPMY) Q2 2020 Earnings Conference Call October 30, 2020 01:00 AM ET Company Participants Kenji Yasukawa - President & Chief Executive Officer Naoki Okamura - Representative Director & Executive Vice President Yukio Matsui - Chief Commercial Officer Mike Kitagawa...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q2 earnings call. For further details see: Astellas Pharma Inc. 2020 Q2 - Results - Earnings Call Presentation

Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...